Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30693019 | 1.00 | POLB (0.72) | POLBALDH1A1SMN1; SMN2CYP2D6GAA | |
| SCHEMBL3196506 | 0.89 | ALDH1A1 (0.70) | POLBALDH1A1SMN1; SMN2CYP2D6GAA | |
| SCHEMBL23089669 | 0.85 | POLB (0.90) | POLBALDH1A1CYP2D6GAALMNA | |
| SCHEMBL2977562 | 0.85 | POLB (0.97) | POLBALDH1A1SMN1; SMN2CYP2D6GAA | |
| SCHEMBL14134639 | 0.84 | POLB (1.00) | POLBALDH1A1CYP2D6GAALMNA | |
| SCHEMBL24025451 | 0.84 | HTT (0.67) | POLBSMN1; SMN2LMNAKMT2A | |
| SCHEMBL29279181 | 0.83 | POLB (0.74) | POLBALDH1A1SMN1; SMN2CYP2D6GAA | |
| SCHEMBL29693728 | 0.81 | POLB (0.63) | POLBALDH1A1SMN1; SMN2CYP2D6GAA | |
| SCHEMBL19951018 | 0.81 | ALDH1A1 (0.67) | POLBALDH1A1SMN1; SMN2GAALMNA | |
| SCHEMBL31372420 | 0.81 | ALDH1A1 (0.67) | POLBALDH1A1SMN1; SMN2GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1961748-A2 | 2-hydroxy-3-heteroarylindole derivatives as GSK3 inhibitors | AstraZeneca AB (SE) | 2008-08-27 | — | — | EP | claimed |
| EP-1667990-A2 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2006-06-14 | — | — | EP | claimed |
| US-20050153987-A1 | Compounds | ASTRAZENECA AB (SE) | 2005-07-14 | — | — | US | claimed |
| WO-2005027823-A2 | 3-HETEROCYCLYL-INDOLE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) | ASTRAZENECA AB (SE) | 2005-03-31 | — | — | WO | claimed |
| EP-1492785-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | claimed |
| WO-2003082853-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2003-10-09 | — | — | WO | claimed |
| WO-2023235925-A1 | COMPOUNDS WITH MERTK ACTIVITY | MONASH UNIVERSITY (AU) | 2023-12-14 | — | — | WO | disclosed |
| US-20200071326-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS INC (US) | 2020-03-05 | — | — | US | disclosed |
| US-9771330-B2 | Pyrimidine compounds for the treatment of cancer | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771330-B2 | Pyrimidine compounds for the treatment of cancer | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771330-B2 | Pyrimidine compounds for the treatment of cancer | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-09-26 | — | — | US | disclosed |
| US-9649309-B2 | Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-05-16 | — | — | US | disclosed |
| US-9649309-B2 | Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-05-16 | — | — | US | disclosed |
| CN-1726042-A | Benzo[d]azepine derivatives for the treatment of neurological disorders | GLAXO GROUP LTD (GB) | 2006-01-25 | — | — | CN | disclosed |
| US-20050153987-A1 | Compounds | ASTRAZENECA AB (SE) | 2005-07-14 | — | — | US | disclosed |
| WO-2005027823-A2 | 3-HETEROCYCLYL-INDOLE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) | ASTRAZENECA AB (SE) | 2005-03-31 | — | — | WO | disclosed |
| EP-1492785-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003082853-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2003-10-09 | — | — | WO | disclosed |
| US-4548935-A | Dihydropyridine anti-ischaemic and anti-hypertensive agents, compositions and use | PFIZER INC. (US) | 1985-10-22 | — | — | US | disclosed |
| EP-0150939-A1 | Dihydropyridine anti-ischaemic and antihypertensive agents | Pfizer Limited (GB) | 1985-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071326-A1 | TAM KINASE INHIBITORS | PIK3CA, MAP3K1, MAP3K5 | POLB 2610/4885ALDH1A1 3459/4885SMN1; SMN2 4570/4885 |
| US-20050153987-A1 | Compounds | SDHA, CYP11B2, CYP11B1 | POLB 1833/4885ALDH1A1 228/4885SMN1; SMN2 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.